Metagenomi not panicking despite Moderna ending deal

mRNA specialist Moderna (Nasdaq: MRNA) has opted to end its collaboration with fellow US biotech Metagenomi on primary hyperoxaluria type 1 (PH1).

Rights to develop the PH1 program, as well as all other rights granted under the collaboration, will be returned as part of the termination.

"With this announcement, we continue to have the opportunity to accelerate our mission to become the premier gene editing company"The original deal - reportedly worth up to $70 million upfront and potentially $3 billion in total - was agreed in late 2021.